RPG Life Sciences Limited has informed the Exchange about Investor Presentation
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
RPG Life Sciences submitted its investor presentation ahead of the Annual Investor Conference held on June 3, 2025. The company highlighted FY25 results with revenue of Rs. 653.4 crores (up 12% year-on-year), EBITDA margin expanding 312 basis points to 26.4% (from 23.3% in FY24), PBT of Rs. 168.2 crores (up 28%), EPS of Rs. 67.5, and zero debt on the balance sheet. ROCE stood at 24.3% and ROE at 32.9%, while market capitalisation grew 49% during the year. Key brands like Naprosyn crossed Rs. 76 crores and are on track to become the company's first Rs. 100 crore brand. The company announced a capex of around Rs. 140 crores for plant and R&D modernisation and outlined an M&A framework with multiple proposals under evaluation for inorganic growth.
This is a positive disclosure showcasing strong margin expansion, debt-free status, robust return ratios, and a clear growth roadmap including potential acquisitions. For shareholders, it reinforces confidence in the company's earnings quality and future growth levers, which could support the stock's premium valuation relative to broader benchmarks.